-+ 0.00%
-+ 0.00%
-+ 0.00%

Corvus Pharmaceuticals Presents Soquelitinib Atopic Dermatitis Trial Data

PUBT·11/05/2026 23:57:46
Listen to the news
Corvus Pharmaceuticals Presents Soquelitinib Atopic Dermatitis Trial Data
  • Corvus Pharmaceuticals expects soquelitinib SIERRA1 Phase 2 atopic dermatitis topline data in the third quarter of 2027.
  • PTCL Phase 3 interim futility analysis is due in the first quarter of 2027, with topline data expected at year-end.
  • Phase 1 atopic dermatitis results showed 75% achieved EASI75; no serious adverse events occurred.
  • Initial hidradenitis suppurativa Phase 1b data are expected in the first half of 2027.
  • Cash runway extends into the second quarter of 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.